Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities.
Kilsgård. Ola O; Andersson. Pia P; Malmsten. Martin M; Nordin. Sara L SL; Linge. Helena M HM; Eliasson. Mette M; Sörenson. Eva E; Erjefält. Jonas S JS; Bylund. Johan J; Olin. Anders I AI; Sørensen. Ole E OE; Egesten. Arne A
Key Findings
- PAD2 and PAD4 in smokers/COPD lungs citrullinate LL‑37, converting arginine residues to citrulline
- Citrullinated LL‑37 has reduced antibacterial activity against Staph aureus, Streptococcus pneumoniae, and Haemophilus influenzae, but retains some activity against Pseudomonas aeruginosa
- The modified peptide shows higher chemotactic activity, lower endotoxin neutralization, and is more rapidly degraded by proteases
Practical Outcomes
- If you smoke or have lung inflammation, LL‑37 supplements may work less well because the peptide gets altered. Reducing inflammation or using PAD‑inhibiting strategies could help preserve LL‑37 activity. Also, expect faster breakdown of the peptide, so dosing frequency might need adjustment.
Summary
The study shows that enzymes called PAD2 and PAD4, which are higher in smokers and people with COPD, change the natural antimicrobial peptide LL‑37 into a modified form. This change makes LL‑37 weaker at killing common lung bacteria, makes it attract immune cells more, but also makes it break down faster and less able to neutralize harmful bacterial components. For anyone using LL‑37 as a supplement, the findings suggest its effectiveness can be reduced by lung inflammation or smoking.
Abstract
Bacterial colonization of the lower respiratory tract is frequently seen in chronic obstructive pulmonary disease (COPD), and may cause exacerbations leading to disease progression. Antimicrobial peptides comprise an important part of innate lung immunity, and not least the cathelicidin human cationic antimicrobial protein-18/LL-37. Peptidylarginine deiminases (PADIs) post-translationally modify proteins by converting cationic peptidylarginine residues to neutral peptidylcitrulline. An increased presence of PADI2 and citrullinated proteins was demonstrated in the lungs of smokers. In this study, preformed PADI4, stored in granulocytes and extracellularly in the lumina of bronchi, was found in lung tissue of individuals suffering from COPD. In vitro, recombinant human PADI2 and PADI4 both caused a time- and dose-dependent citrullination of LL-37. The citrullination resulted in impaired antibacterial activity against Staphylococcus aureus, Streptococcus pneumoniae, and nontypable Haemophilus influenzae, but less so against Pseudomonas aeruginosa. Using artificial lipid bilayers, we observed discrete differences when comparing the disrupting activity of native and citrullinated LL-37, suggesting that differences in cell wall composition are important during interactions with whole bacteria. Furthermore, citrullinated LL-37 showed higher chemotactic activity against mononuclear leukocytes than did native LL-37, but was less efficient at neutralizing lipolysaccharide, and also in converting apoptotic neutrophils into a state of secondary necrosis. In addition, citrullinated LL-37 was more prone to degradation by proteases, whereas the V8 endopetidase of S. aureus cleaved the modified peptide at additional sites, compared with native LL-37. Together, these findings demonstrate novel mechanisms whereby the inflammation-dependent deiminases PADI2 and PADI4 can alter the activites of antibacterial polypeptides, affecting the course of inflammatory disorders such as COPD.
Study Information
pubmed
2011
2011-09-29T00:00:00.000Z
10.1165/rcmb.2010-0500oc